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Abstract: Histone modification enzymes regulate gene expression by altering the 
accessibility of promoters to transcription factors. We sought to determine whether the 
genes encoding histone modification enzymes are dysregulated in pediatric acute 
lymphoblastic leukemia (ALL). A real-time PCR array was designed, tested and used to 
profile the expression of 85 genes encoding histone modification enzymes in bone marrow 
mononuclear cells from 30 pediatric ALL patients and 20 normal controls. The expression 
profile of histone-modifying genes was significantly different between normal karyotype B 
cell pediatric ALL and normal controls. Eleven genes were upregulated in pediatric ALL, 
including the histone deacetylases HDAC2 and PAK1, and seven genes were downregulated, 
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including PRMT2 and the putative tumor suppressor EP300. Future studies will seek to 
determine whether these genes serve as biomarkers of pediatric ALL. Ingenuity Pathway 
Analysis revealed that Gene Expression and Organ Morphology was the highest rated 
network, with 13 focus molecules (significance score = 35). Ingenuity Pathway Analysis 
also indicated that curcumin and miR-34 are upstream regulators of histone-modifying 
enzymes; future studies will seek to validate these results and examine the role of curcumin 
and miR-34 in leukemia. This study provides new clues into the molecular mechanisms of 
pediatric ALL. 
Keywords: histone-modifying enzymes; pediatric acute lymphoblastic leukemia;   
real-time PCR array 
 
1. Introduction 
Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, 
representing nearly one third of all pediatric cancers [1–4]. Over the last decade, advances in the 
treatment of pediatric ALL have led to long-term event-free survival rates of approximately 80%. 
Despite the good overall prognosis, some of the less common subtypes of ALL have a high risk of 
relapse [1–4]. Rearrangements of the myeloid/lymphoid or mixed-lineage leukemia (MLL) gene at 
chromosome band 11q23 are detected in least 10% of cases and are associated with aggressive 
pediatric ALL. Unfortunately, young children with this genetic abnormality have a very poor prognosis 
and a survival rate of less than 20%, even after intensive therapy [5]. The MLL gene encodes a   
DNA-binding protein which methylates histone H3 lysine 4 (H3K4). MLL is a member of the group of 
histone-modifying enzymes, which is commonly disrupted in leukemia [6,7]. MLL translocations 
encode MLL fusion proteins which lack H3K4 methyltransferase activity, which results in abnormal 
histone modification [8,9].  
Histone-modification provides an important regulatory platform for processes such as gene 
expression, DNA replication and repair, chromosome condensation and segregation and apoptosis. 
Disruption of these processes has been linked to the multistep process of carcinogenesis [10]. 
Alterations in histone-modifying enzymes can contribute to the development of a variety of human 
cancers. The new terminology “histone onco-modifications” has been proposed to describe the   
post-translational histone modifications linked to cancer [11,12]. Histones are the chief protein 
components of chromatin, acting as the spools around which DNA winds. Histones are no longer 
considered to be simple “DNA packaging” proteins, and are currently recognized to be regulators of 
chromatin dynamics. Histones are subject to a wide variety of post-translational modifications, 
including acetylation of lysines, methylation of lysines and arginines, serine and threonine 
phosphorylation, lysine ubiquitylation, glycosylation, sumoylation, adenosine diphosphate   
ribosylation and carbonylation, all of which are dynamically catalyzed by histone-modifying enzyme  
complexes [13,14]. Histone modifications influence chromatin-templated processes such as gene 
transcription, DNA repair and recombination. Histone lysine methylation and acetylation are 
enzymatically reversible processes which are “written” by lysine methyltransferases (KMTs) [15] and Int. J. Mol. Sci. 2013, 14 3378 
 
 
lysine acetyltransferases (KATs) [16], and “erased” by lysine demethylases (KDMs) [17–21] and 
histone deacetylases (HDACs) [22]. Overall, post-translational histone modifications provide an 
epigenetic mechanism for the regulation of a variety of normal and cancer-related processes. Growing 
evidence suggests that histone-modifying enzymes are dysregulated in human cancer. In fact, an 
extensive analysis of the expression patterns of histone-modifying enzymes could discriminate 
between tumor samples and their normal counterparts, and also cluster the tumor samples according to 
cell type [10]. However, little is currently known about the histone modification changes which occur 
during the development and progression of pediatric ALL.  
Real-time PCR array systems are an ideal tool for analyzing the expression of a focused panel of 
genes [23]. The specificity of real-time PCR guarantees the amplification of a single gene-specific 
product in each reaction, allowing the expression level results to confidently reflect only the gene of 
interest. PCR arrays can determine the gene expression differences between two RNA samples, with 
results that are highly concordant with other quantitative gene expression analysis and microarray 
platforms. PCR arrays also deliver results comparable to high-density microarrays, as well as TaqMan 
Gene Expression Assays, a widely accepted method for validating the results of microarrays and other 
more complicated and expensive quantitative methods based on TaqMan assays [24]. In this study, we 
sought to analyze the mRNA expression profiles of histone-modifying enzymes in pediatric ALL using 
a powerful real-time PCR array platform. 
2. Results and Discussion 
2.1. Real-Time PCR Array Design 
We designed and tested 88 real-time PCR primer pairs for quantitative gene expression analysis of 
genes involved in pediatric ALL. The primers for the target genes are listed in Supplementary File 1. 
Real-time PCR primers for histone-modifying enzymes. The human histone-modifying enzymes PCR 
array was designed to profile the expression of 85 key genes, which encode enzymes known or 
predicted to modify genomic DNA or histones to regulate chromatin accessibility, and therefore gene 
expression. De novo and maintenance DNA methyltransferases, and the enzymes responsible for the 
demethylation of CpG dinucleotides were represented on the array, NOTCH signaling, (NOTCH1, 
NOTCH2, EP300) and DNA methyltransferases (DNMT1, DNMT3A, DNMT3B). Enzymes catalyzing 
histone acetylation, methylation, phosphorylation, and ubiquitination were also included on the array, 
as well as deacetylases and demethylases. The genes included were the histone acetyltransferases: 
ATF2, CDYL, CIITA, CSRP2BP, ESCO1, ESCO2, HAT1, KAT2A (GCN5L2), KAT2B (PCAF), KAT5 
(HTATIP),  KAT8,  KAT7,  KAT6A,  KAT6B,  NCOA1,  NCOA3,  NCOA6; histone methyltransferases: 
CARM1 (PRMT4),  DOT1L,  EHMT2,  MLL,  MLL3,  PRMT1,  PRMT2,  PRMT3,  PRMT5,  PRMT6, 
PRMT7, PRMT8, SETDB2, SMYD3; enzymes of histone phosphorylation: AURKA, AURKB, AURKC, 
NEK6,  PAK1,  RPS6KA3,  RPS6KA5; enzymes of histone ubiquitination: DZIP3,  RNF2,  RNF20, 
UBE2A, UBE2B, USP16, USP21, USP22; DNA/histone demethylases: KDM1A, KDM5B, KDM5C, 
KDM4A, KDM4C, MBD2; and histone deacetylases: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, 
HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, HDAC11. The array also included genes encoding 
Drosophila [Su(var), E(z) and Trithorax] (SET) domain proteins, all of which contain a homologous Int. J. Mol. Sci. 2013, 14 3379 
 
 
domain that confers histone methyltransferase activity in some family members, SET Domain Proteins 
(Histone Methyltransferase Activity): ASH1L,  MLL3,  MLL5,  NSD1,  SETD1A,  SETD2,  SETD3, 
SETD4, SETD6, SETD7, SETD8, SETDB1, SUV39H1, SUV420H1, WHSC1.  
2.2. Real-Time PCR Array Testing 
Using real-time PCR, we can easily and reliably analyze the expression of a focused panel of genes 
involved in epigenetic chromatin modifications with this array. Each primer set was tested by 
expression analysis and melting curve analysis, to confirm that the primers were specific for the target 
gene (Figure 1). The flexibility, simplicity and convenience of standard SYBR Green PCR detection 
methodology makes PCR array systems accessible for routine use in any research laboratory.  
Figure 1. Design and testing of the real-time PCR array for human genes encoding 
epigenetic chromatin modification enzymes. (A) Amplification of a target gene and 
GAPDH in the real-time PCR array. Reactions were run on a Light cycler 480 (Roche, 
Basel, Switzerland) using universal thermal cycling parameters (95 °C for 5 min, 45 cycles 
of 10 s at 95 °C, 20 s at 60 °C and 15 s at 72 °C); (B) Melting curve analysis of the PCR 
product of a single target gene. Melting curves were generated using the parameters 10 s at 
95 °C, 60 s at 60 °C, followed by continued melting; (C) Amplification of all of the genes 
in the PCR array.  
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2.3. Expression Profiling of Normal Karyotype B Cell Pediatric ALL and Normal Control Samples 
We analyzed and clustered the gene expression profiles of bone marrow mononuclear cells from  
30 pediatric ALL patients and 20 control samples using the real-time PCR array. The clinical features 
of the 30 pediatric ALL patients and 20 controls are listed in Table 1. We analyzed the original 
expression data using Multi Experiment View (MEV) clustering software. The cluster is not 
successful. This result showed pediatric ALL sample L2, L9, L28, L4, L16, L24, L11, L22, L27, L29 
and L30 are different from other ALL samples. L2 and L9 are T cell ALL. L4 and L16 are B cell ALL 
with MLL fusion gene (Supplementary File 2. Cluster analysis the gene expression in 30 pediatric 
ALL patients and 20 controls samples). Heterogeneous genetic background may affect the expression 
of histone-modifying enzymes. So we do the second cluster, and we only clustered gene expression 
profiles from 18 normal karyotype B cell pediatric ALL patients and 20 control samples The gene 
expression profile in pediatric ALL was significantly different to the normal controls. Specific sets of 
genes clustered in normal karyotype B cell ALL (Figure 2). The most significantly clustered genes are 
shown in Figure 3A. The expression of PAK1 and HDAC2 between normal karyotype B cell ALL and 
normal control was certificated with western-blot (Figure 3B).  
Table 1.  Clinical features of the normal donors and pediatric acute lymphoblastic   
leukemia patients. 
  NBM/ITP Pediatric  ALL 
Age  4.3 (0.7–13.6)  5.1 (0.9–13.6) 
Sex (M/F)  12/8  19/11 
White blood cells (109/L)  8.4 (3.82–16.97)  56.9 (2.1–638) 
Hemoglobin (g/L)  129 (90–157)  81.2 (28–126) 
Platelet count (109/L)  313 (17–498)  49 (8–195) 
Immunophenotyping 
B-ALL ns  28 
T-ALL ns  2 
Risk stratification 
Standard ns  6 
Median ns  8 
High ns  16 
Karyotype 
Normal ns  18 
Abnormal ns  12 
Fusion gene 
MLL ns  2 
TEL/AML1 ns 7 
BCR/ABL1 ns  1 
 E2A/PBX  ns  1 
NBM, Normal Bone Marrow; IPT, Idiopathic Thrombocytopenic Purpura; B-ALL, B cell acute 
lymphoblastic leukemia; T-ALL, T cell acute lymphoblastic leukemia Int. J. Mol. Sci. 2013, 14 3381 
 
 
Figure 2. Expression and clustering analysis of differentially expressed genes encoding 
epigenetic chromatin modification enzymes in pediatric ALL and normal control samples. 
Clustering analysis of the gene expression data from the real-time PCR array. The 
comparative Ct method was used for quantification of gene expression. The gene 
expression levels for each target gene were normalized to the housekeeping gene GAPDH 
within the same sample (−ΔCt); then the relative expression of each gene (n = 87) was 
calculated using 10
6 × Log2(−ΔCt). Gene expression in the normal karyotype B cell 
pediatric acute lymphoblastic leukemia (ALL) (n = 18) and control samples (n = 20) was 
analyzed using Multi Experiment View (MEV) clustering software.  
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The gene expression profile in pediatric ALL was significantly different to the normal controls. 
Specific sets of genes clustered in normal karyotype B cell ALL (Figure 2). The most significantly 
clustered genes are shown in Figure 3A. The expression of PAK1 and HDAC2 between normal 
karyotype B cell ALL and normal control was certificated with western-blot (Figure 3B).  
Figure 3. Expression and clustering analysis of differentially expressed genes encoding 
epigenetic chromatin modification enzymes in pediatric ALL and normal control samples. 
(A) The most significantly clustered genes between normal karyotype B cell ALL and 
normal controls; (B) Western-blot analysis the expression of PAK1 and HDAC2 in 
pediatric ALL and normal control samples.  
 
The 11 genes upregulated in normal karyotype B cell pediatric ALL are listed in Table 2 .The 
expression level of each upregulated gene in pediatric ALL is presented in Figure 4. Some of these 
upregulated genes have previously been studied in leukemia or other tumors. The gene expression 
profile of 12 HDAC genes was previously analyzed by quantitative real-time PCR in 94 consecutive 
cases of childhood ALL [10,25]. The ALL samples showed higher expression levels of HDAC2, 
compared to normal bone marrow samples [10,25], in agreement with this study. The epigenetic regulator 
HDAC2 is often significantly overexpressed in solid tumors, can influence cell proliferation, apoptosis and 
differentiation, and has been suggested as a therapeutically important prognostic marker [26–29].  Int. J. Mol. Sci. 2013, 14 3383 
 
 
Table 2. Genes encoding epigenetic chromatin modification enzymes upregulated in 
normal karyotype B cell pediatric ALL compared with normal controls. 
 Gene  Description  NBM ALL  Change  p value 
1  PAK1  P21 protein (Cdc42/Rac)-activated kinase 1  690.78  8684.84  12.57  3.94 × 10
−17 
2 EHMT2  Euchromatic  histone-lysine  N-methyltransferase  2  1238.91  19701.33 15.90 1.07  ×  10
−15 
3 KAT7  K(lysine)  acetyltransferase  7  13037.87 76644.47  5.88  5.97  ×  10
−9 
4 GCN5L2  K(lysine)  acetyltransferase  2A 6554.99  33808.15 5.16 6.03  ×  10
−9 
5  SUZ12  Suppressor of zeste 12 homolog  24556.24  123398.3  5.03  1.56 × 10
−6 
6  SUV420H1  Suppressor of variegation 4-20 homolog 1  7843.03  44187.54  5.63  1.65 × 10
−6 
7 KAT6B  K(lysine)  acetyltransferase  6B 26130.51  75299.71  2.88  4.19  ×  10
−6 
8  CSRP2BP  CSRP2 binding protein  2041.52  14595.22  7.15  2.25 × 10
−5 
9  RNF20  Ring finger protein 20  10498.77  32675.14  3.11  0.00034 
10  SETD2  SET domain containing 2  14027.6  42467.29  3.02  0.008 
11 HDAC2  Histone  deacetylase  2  9325.25 50147.01 5.38  0.015 
NBM, Normal Bone Marrow. 
Figure 4. Expression of upregulated epigenetic chromatin modification genes in normal 
karyotype B cell pediatric ALL. Expression levels of the significantly upregulated genes in 
normal karyotype B cell pediatric ALL (n = 18), compared to the control samples 
(NBT/IPT; n = 20). Data is presented as the average ± SE; p values <0.05 were considered 
statistically significant. 
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Changes in the levels and activity of p21 protein (Cdc42/Rac)-activated kinase 1 (PAK1) are also 
frequently described in human malignancies [30–33]. This phenomenon has been observed in various 
tumor types using a variety of techniques. The abnormalities reported include gene amplification, 
elevated mRNA and protein expression, and increased accumulation of the phosphorylated and, 
presumably, activated form of this enzyme. There are also intriguing observations regarding the 
accumulation of phosphorylated PAK1 specifically in the nuclei of malignant cells [34], which parallel 
the changes observed during tumor progression in a mouse model [35]. Importantly, elevated levels of 
PAK1 were identified to be an independent prognostic predictor of poor survival in ovarian   
cancer [36]. In breast cancer, nuclear expression of PAK1, in conjunction with phosphorylation of the 
estrogen receptor on the PAK1 site (serine 305), predicts resistance to tamoxifen therapy, and the 
cytoplasmic levels of PAK1 correlate with the recurrence rate and mortality [35,37]. Similarly, higher 
levels of PAK1 were associated with advanced tumor stage, metastasis and reduced survival in patients 
with gastric cancer [38,39]. There are also numerous reports of elevated PAK1 activity in cell lines, 
although in most of these cases such reports cannot rule out the possibility that the changes have been 
selected for or caused by in vitro culture.  
The seven genes downregulated in pediatric ALL are listed in Table 3, and the expression level of 
each downregulated gene in pediatric ALL is presented in Figure 5. The putative tumor suppressor 
gene EP300 is located on chromosome 22q13, a region which shows frequent loss of heterozygosity 
(LOH) in colon, breast and ovarian cancer. LOH across the EP300 locus was detected in 38% of colon, 
36% of breast, and 49% of ovarian primary tumors; however, no somatic mutations in EP300 have 
been identified in any primary tumor [40,41]. EP300 is a histone acetyltransferase that regulates 
transcription via chromatin remodeling, and plays an important role in the processes of cell 
proliferation and differentiation. EP300 acetylation of tumor protein P53 (TP53) in response to DNA 
damage regulates the DNA-binding and transcription functions of TP53 [42]. The tumor suppressor 
gene protein arginine methyltransferase 2 (PRMT2) inhibits nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 1 (NF-κB)-dependent transcription and promotes apoptosis, by blocking 
nuclear export of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
(IκB-α) via a leptomycin-sensitive pathway, which increases nuclear IκB-α accumulation and 
decreases NF-κB DNA binding [43–46]. The highly conserved S-adenosylmethionine-binding domain 
of PRMT2 mediates this effect. PRMT2 also renders cells susceptible to apoptosis induced by 
cytokines or cytotoxic drugs, most likely due to the effects of PRMT2 on NF-κB. Mouse embryo 
fibroblasts from PRMT2 genetic knockouts have elevated NF-κB activity and decreased susceptibility 
to apoptosis, compared to wild-type or complemented cells. These data suggest that PRMT2 inhibits 
cell activation and promotes programmed cell death through a NF-κB-dependent mechanism. Int. J. Mol. Sci. 2013, 14 3385 
 
 
Table 3. Genes encoding epigenetic chromatin modification enzymes downregulated in 
normal karyotype B cell pediatric ALL compared with normal controls. 
 Gene  Description  NBM ALL  Change  p value 
1  HDAC5  Histone deacetylase 5  11379.83 186.94  0.01  2.67 × 10
−27
2  NOTCH2  Notch homolog 2  32473.8  319.09  0.01  3.05 × 10
−27
3  NOTCH1  Notch homolog 1  13109.41 1089.23  0.05  9.19 × 10
−15
4  EP300  E1A binding protein p300  47487.19 5601.60  0.12  1.37 × 10
−13
5  PRMT2  Protein arginine methyltransferase 2  28388.11 6336.82  0.22  2.08 × 10
−12
6 DNMT3A DNA  (cytosine)  methyltransferase 3 alpha 3868.084 682.15  0.17  2.04 × 10
−12
7  RPS6KA3  Ribosomal protein S6 polypeptide 3  20389.11 5203.03  0.25  1.00 × 10
−5 
NBM, Normal Bone Marrow. 
Figure 5. Expression of downregulated epigenetic chromatin modification genes in normal 
karyotype B cell pediatric ALL. Expression levels of the significantly downregulated genes 
in normal karyotype B cell pediatric ALL (n = 18), compared to the control samples 
(NBT/IPT; n = 20). Data is presented as the average ± SE; p values <0.05 were considered 
statistically significant. 
 
2.4. Ingenuity Pathway Analysis of Dys-regulated Genes in Normal Karyotype B cell Pediatric ALL  
To investigate the possible biological interactions between the differently regulated genes in 
pediatric ALL, the datasets derived from the real-time PCR array analyses were imported into the 
Ingenuity Pathway Analysis (IPA) Tool. IPA analysis of the genes with a significantly altered 
expression profile in ALL revealed two significant networks (Figure 6A). Of these networks, Gene Int. J. Mol. Sci. 2013, 14 3386 
 
 
Expression and Organ Morphology was the highest rated network, with 13 focus molecules and a 
significance score of 35 (Figure 6D).The score is the probability that a collection of genes equal to or 
greater than the number of genes in the network could be achieved by chance alone. A score of 3 
indicates a 1/1000 chance that the focus genes are not in the network due to random chance. The IPA 
analysis also grouped the differentially expressed genes in pediatric ALL into a number of other 
biological mechanisms related to Phospholipase C Signaling (1.79 × 10
−4), HMGB1 Signaling   
(2.22 × 10
−4), DNA methylation and Transcriptional Repression Signaling (2.99 × 10
−4), Hereditary 
Breast Cancer Signaling (3.84 × 10
−4) and Nocth Signaling (1.03 × 10
−3, Figure 6B). Further results of 
the IPA analysis are provided in Supplementary File 3. IPA analysis of the significantly dys-regualted 
histone-modifying enzymes in pediatric ALL. 
Figure 6. Summary of Ingenuity Pathway Analysis for dys-regulated epigenetic chromatin 
modification genes in normal karyotype B cell pediatric ALL. To investigate possible 
interactions between the differently regulated genes in pediatric ALL, datasets representing 
the 18 significantly altered genes were imported into the Ingenuity Pathway Analysis (IPA) 
Tool. (A) Top two networks obtained from IPA (with their respective scores) for the 
differently regulated genes in pediatric ALL; (B) Toxicology pathway list obtained from 
IPA analysis for the differently regulated genes in pediatric ALL. The x-axis represents the 
most significant toxicology functions based on the differentially expressed genes are 
highlighted; the y-axis represents the number of genes from the dataset that map to the 
pathway and the number of all known genes ascribed to the pathway. The yellow line 
represents the threshold p value (0.05), as calculated by Fisher’s test; (C) Upstream 
regulator list for the differently regulated genes in pediatric ALL. Curcumin and mir-34 
were the two most significant upstream regulators of the differently regulated genes in 
pediatric ALL; (D) Network representation of the most highly rated network for the 
differently regulated genes in pediatric ALL. The shaded genes are statistically significant. 
Solid lines represent a direct interaction between two gene products, dotted lines represent 
indirect interactions; (E) Mapping of the genes associated with the upstream regulators for 
the differently regulated genes in pediatric ALL. 
 Int. J. Mol. Sci. 2013, 14 3387 
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The IPA analysis also revealed that curcumin and mir-34 signaling were the two most important 
upstream regulators for the dysregulated histone-modifying enzymes in pediatric ALL, with p values 
of 2.83 × 10
−6 and 2.45 × 10
−5, respectively (Figure 6C). The genes associated with the upstream 
regulators are mapped in Figure 4E. Ectopic expression of miR-34 genes leads to marked effects on 
cell proliferation and survival, due to cell-cycle arrest in the G1 phase [47,48]. Interestingly, the 
introduction of miR-34a and miR-34b/c induced cellular senescence in primary human diploid 
fibroblasts, and overexpression of miR-34a induced apoptosis in tumor cells. MiR-34a has been shown 
to target and translationally repress sirtuin 1 (SIRT1) mRNA [49–51]. SIRT1, a histone-modifying 
enzyme, is a NAD-dependent deacetylase which has been shown to inhibit the activity of several  
pro-apoptotic proteins. Regulation of SIRT1 by miR-34a forms part of a positive feedback loop which 
leads to enhanced activation of p53, once it has been initially activated. This study provides the first 
indication that other histone-modifying enzymes, in addition to SIRT1, may be dys-regulated by   
miR-34 in pediatric ALL.  
The other upstream regulator of histone-modifying enzymes in normal karyotype B cell pediatric 
ALL revealed in this study was curcumin (diferuloylmethane), which is a polyphenol derived from the Int. J. Mol. Sci. 2013, 14 3388 
 
 
plant Curcuma longa, commonly known as turmeric. Recently, curcumin has been found to possess 
anti-cancer activity, as it exerts a number of effects on a variety of biological pathways involved in 
mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigenesis and metastasis. 
Curcumin has demonstrated anti-proliferative effects in multiple types of cancer, and is an inhibitor of 
the transcription factor NF-κB and its downstream gene products including c-MYC, BCL-2, COX-2, 
NOS, Cyclin D1, TNF-α, interleukins and MMP-9. In addition, curcumin affects a variety of growth 
factor receptors and cell adhesion molecules involved in tumor growth, angiogenesis and metastasis. 
Cultured leukemia cells are particularly responsive to curcumin [52–54]. As of 2011, more than 75 
studies in peer-reviewed journals have reported that curcumin induces apoptosis and cell death in 
cultured animal and human leukemia cells. This study is the first to imply that curcumin may affect 
cancer cell growth and apoptosis via regulation of histone-modifying enzymes. In the future, we   
will seek to validate these results, and examine the role of curcumin and miR-34 in the molecular  
basis of leukemia. 
3. Experimental Section  
3.1. Patients and Samples  
Bone marrow specimens were obtained at the time of diagnosis during routine clinical assessment 
of 30 patients with ALL, who presented at the Department of Hematology and Oncology, Children’s 
Hospital of Soochow University between 2010 and 2012. Ethical approval was provided by the 
Children’s Hospital of Soochow University Ethics Committee (No.SUEC2010-011 and   
No. SUEC2009-219-1), and informed consent was obtained from the parents or guardians. The main 
clinical and laboratory features of the patient cohort are summarized in Table 1. Additionally, bone 
marrow samples from 10 healthy donors from surgical operations and 10 patients with idiopathic 
thrombocytopenic purpura (ITP) were analyzed as controls. Bone marrow mononuclear cells 
(BMNCs) were isolated using Ficoll solution within 2 h after harvest. 
3.2. RNA Extraction 
BMNCs were immediately submerged in 4 mL TRIzol (Invitrogen, Carlsbad, CA, USA), and stored 
at −80 °C until further processing. A volume of 1.2 mL from each sample was centrifuged at 12,000g 
for 15 min at 4 °C to remove debris and DNA, then 1 mL of the supernatant was mixed with 200 µL 
chloroform, shaken for 15 seconds, incubated at RT for 2–3 min and centrifuged at 12,000g for 10 min 
at 4 °C. RNA was precipitated by adding 500 µL of the aqueous phase to an equal volume of 
isopropanol and centrifugation at 14,000g for 10 min at 4 °C. The RNA pellet was washed with 75% 
ethanol, centrifuged at 14,000g for 10 min at 4 °C, dried and resuspended in 60 µL DEPC-treated  
H2O. The final RNA concentration of the samples was determined using a spectrophotometer   
(Nanodrop 2000, Thermo-scientific, Wilmington, DE, USA) and the purity of the RNA samples was 
assessed by agarose gel electrophoresis. Int. J. Mol. Sci. 2013, 14 3389 
 
 
3.3. Synthesis of cDNA  
Synthesis of cDNA was performed using 4 µg of RNA in 10 µL reactions with SuperScript II 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA), as recommended by the manufacturer. The 
RNA was incubated with 0.5 µg of oligo(dT)12–18mers primers (Invitrogen) for 7 min at 70 °C and 
then transferred onto ice. Then, 9 µL of a master mix containing 4 µL of SuperScript II buffer, 2 µL of 
0.1 M DTT (Invitrogen), and 1 µL each of dNTPs (10 mM; Invitrogen), RNasin (40 UI; Promega, 
Madison, WI, USA) and SuperScript II (Invitrogen) were added, centrifuged and incubated at 42 °C 
for 60 min, followed by 5 min at 70 °C to inactivate the enzyme; the cDNA was stored at −20 °C. 
3.4. Real-Time PCR Array Design and Testing 
Most of the primers were obtained from the database of real-time primers curated by the Center for 
Medical Genetics (http://medgen.ugent.be/CMGG/). The remainders of the primers were designed 
using the online program Primer 3 (www.fokker.wi.mit.edu/primer3/input.htm). The primer selection 
parameters were primer size: 20–26 nts; primer melting temperature: 60 °C to 64 °C; GC clamp: 1; and 
product size range: generally 120–240 bp, but reduced to 100 bp if no appropriate primers could be 
identified. The sequences of the primers are listed in Supplementary File 1. All of the primers were 
synthesized by Invitrogen.  
3.5. Real-Time PCR Array Analysis 
Real-time PCR array analysis was performed in a total volume of 20 µL including 2 µL of cDNA, 
primers (0.2 mM each) and 10 µL of SYBR Green mix (Roche, Basel, Switzerland). Reactions were 
run on an Light cycler 480 (Roche, Basel, Switzerland) using universal thermal cycling parameters  
(95 °C for 5 min, 45 cycles of 10 s at 95 °C, 20 s at 60 °C and 15 s at 72 °C; followed by a melting 
curve: 10 s at 95 °C, 60 s at 60 °C and continued melting). The results were obtained using the 
sequence detection software of the Light cycler 480 and analyzed using Microsoft Excel. For quality 
control purposes, melting curves were acquired for all samples. The comparative Ct method was used 
to quantify gene expression. Firstly, the target gene expression level was normalized to expression of 
the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) within the same sample 
(−ΔCt), and then the relative expression of each gene was calculated using 10
6 × Log2 (−ΔCt). The 
gene expression of the pediatric ALL and control samples was presented as the average ± SE.  
3.6. Western Blot Analysis 
For western blot analysis, cellular proteins were extracted in 40 mM Tris–HCl (pH 7.4) containing 
150 mM NaCl and 1% (v/v) Triton X-100, supplemented with a cocktail of protease inhibitors. Equal 
amounts of protein were resolved on 12% SDS-PAGE gels, and then transferred to a PVDF membrane 
(Millipore, Bedford, MA, USA). Blots were blocked and then probed with antibodies against PAK1 
(1:1000, Cell Signaling Technology, Inc., Danvers, MA, USA), HDAC2 (1:1000, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA), GAPDH (1:5000, Sigma, St. Louis, MO, USA). After 
washing, the blots were incubated with horseradish peroxidase-conjugated secondary antibodies and Int. J. Mol. Sci. 2013, 14 3390 
 
 
visualized by enhanced chemiluminescence kit (Pierce, Rockford, IL, USA). Protein bands were 
visualized after exposure of the membrane to Kodak X-ray film. 
3.7. Ingenuity Pathway Analysis (IPA) 
Datasets derived from the real-time PCR array analyses, representing genes with significantly 
altered expression profiles, were imported into the Ingenuity Pathway Analysis Tool (IPA Tool; 
Ingenuity H Systems, Redwood City, CA, USA; http://www.ingenuity.com). In IPA, differentially 
expressed genes are mapped to the genetic networks available in the Ingenuity database, and then 
ranked by score. The Ingenuity Pathway Knowledge Base (IPKB) forms the basis of IPA, and is 
derived from known gene functions and interactions published in the literature. Thus, IPA enables the 
identification of biological networks, global functions and functional pathways for a particular dataset. 
The program also calculates the significance of the genes in the network, the other genes with which it 
interacts, and how the products of the genes directly or indirectly act on each other, including those not 
involved in the microarray analysis. The networks created are ranked, depending on the number of 
significantly expressed genes they contain, and also the list of significant, relevant diseases. A network 
is a graphical representation of the molecular relationships between molecules. Molecules are 
represented as nodes, and the biological relationship between two nodes is represented as an edge 
(line). All edges are supported by at least one reference from the literature, a textbook, or canonical 
information stored in the Ingenuity Pathways Knowledge Base. The intensity of the node color 
indicates the degree of upregulation (red) or downregulation (green). Nodes are displayed using 
various shapes that represent the functional class of the gene product. 
3.8. Statistical Analysis 
The significance of the differences in the gene expression profiles of pediatric ALL and the control 
samples were calculated using unpaired t-tests with SPSS version 11.5 (SPSS Inc., Chicago, IL, USA); 
p values <0.05 were considered statistically significant. 
4. Conclusions  
We successfully designed and tested a real-time PCR array for analysis of the genes encoding 
human epigenetic chromatin modification enzymes. Using this array, we demonstrated the different 
mRNA expression patterns of human histone-modifying enzymes in normal karyotype B cell pediatric 
ALL and normal controls. A lot of genes can be significantly clustered in the gene and sample 
analysis, including the histone deacetylases HDAC2 which was upregulated in normal karyotype B cell 
pediatric ALL, PRMT2 and the putative tumor suppressor gene EP300 which were downregulated in 
pediatric ALL. We identified a number of dysregulated histone-modifying enzymes in normal 
karyotype B cell pediatric ALL, which have not previously been reported to be differently expressed in 
pediatric ALL. Future studies will seek to determine whether these dys-regulated histone-modifying 
enzymes can serve as biomarkers of pediatric ALL. Additionally, IPA indicated that curcumin and 
miR-34 may be the major upstream regulators of histone-modifying enzymes in normal karyotype B 
cell pediatric ALL, future studies will seek to validate these results, and examine the role of curcumin Int. J. Mol. Sci. 2013, 14 3391 
 
 
and miR-34 in the molecular basis of leukemia. This work provides new clues regarding the molecular 
mechanisms which regulate the development of normal karyotype B cell pediatric ALL. 
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